Everest Medicines Expands Strategic Investment in I-MAB to Advance the Global Value of Its Proprietary Next-Generation Cancer Immunotherapies

HONG KONG, Aug 2, 2025 – (ACN Newswire) –Everest Medicines (HKEX: 1952. HK) today revealed a tactical equity financial investment in I-Mab (NASDAQ: IMAB), under which Everest will invest US$ 30.9 million (equivalent to roughly HK$ 242.6 million) in money. Upon conclusion of the membership and inclusive of shares currently held, Everest will own roughly 16.1% of I-Mab’s overall exceptional shares.

Under the regards to the arrangement of this offering, Everest will subscribe for 15,846,154 freshly provided American depositary shares (ADSs) of I-Mab at a rate of US$ 1.95 per ADS, for an overall factor to consider of US$ 30.9 million. Upon conclusion, Everest will hold an overall of 15,846,154 ADSs and 6,078,571 regular shares, representing roughly 16.1% of I-Mab’s overall provided share capital, inclusive of 6,078,571 regular shares it currently owns. In addition to Everest, numerous leading worldwide institutional financiers are taking part in this offering, consisting of Janus Henderson Investors, Adage Capital Partners LP, Woodline Partners, and Exome Asset Management.

This tactical financial investment marks a considerable action in Everest’s continuous efforts to reinforce its position in next-generation cancer immunotherapy. It likewise shows the strong medical and company advancement complementarity and synergy in between the 2 business. I-Mab’s Claudin 18.2 x 4-1BB bispecific antibody, givastomig, showed an outstanding general action rate (ORR) of 83% in mix with immunotherapy in a Phase 1b trial for first-line stomach cancer. I-Mab’s separated 4-1BB receptor-targeting platform and bispecific antibody pipeline are extremely complementary with Everest’s existing mRNA cancer vaccine and in vivo CAR-T platforms.

In addition, I-Mab’s distinct medical translational abilities, especially in the U.S., integrated with Everest’s medical abilities in Asia, might assist speed up the advancement and international growth of pipeline items for both business.

“This tactical equity financial investment advances our strategy to be an active gamer in next-generation oncology programs throughout international markets. Everest and its Board of Directors think this financial investment acknowledges I-Mab’s distinct scientific translational abilities in the U.S., which are complementary and synergistic with the Company’s strong Asia existence,” stated Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “As a biotech leader in China, Everest has actually constructed internally established pipeline properties consisting of mRNA healing cancer vaccines and in vivo CAR-T treatments targeting cancer and autoimmune illness. Our locations of focus meaningfully converge with I-Mab’s distinguished 4-1BB platform and bispecific antibody pipeline, consisting of oncology prospects Givastomig (Claudin 18.2 x 4-1BB bispecific antibody) and Ragistomig (PD-L1 x 4-1BB bispecific antibody), both appealing programs that we are carefully seeing. Both business might be able to utilize their combined proficiency to run scientific programs in both China and the U.S. Everest is happy to establish ingenious and important treatments that can benefit cancer clients internationally.”

The tactical equity financial investment not just reinforces Everest Medicines’ position in next-generation immuno-oncology, however likewise extends the international advancement course of its exclusive AI-powered mRNA platform. As an essential pillar of Everest’s “dual-engine” technique of in-licensing and internal development, the business has actually made strong development in structure and internationalizing its AI+mRNA platform. Numerous pipeline programs are advancing in preclinical research study, with a strong concentrate on oncology and autoimmune illness. Looking ahead, Everest will speed up worldwide medical advancement and regulative efforts, while actively checking out cooperations with prominent worldwide biopharmaceutical business to optimize the worth of its platform and bring advancement treatments to clients worldwide.

Subject: Press release summary